Betta Pharmaceuticals Co., Ltd.

Beta Pharma, Inc.

Lieming Ding

Wei Long

Yinxiang Wang

Jiabing Wang

Shaojing Hu

Yunyan Hu

Fenlai Tan

Fei Wang

Xiaofeng Xu

Yiqian Wang

Wei He

Yan Xu

Yong Liu

Guojian Xie

Charles Davis

Haima Ai

Yao Zhang

Chao Wang

Yanping Wang

Don Zhang

Bin Han

Hong Cao

Cunbo Ma

Xiangdong Zhao

Wei Wang

Chunhui Zhang

Hao Wu

Jun Yu

Xiangyong Liu

Yabin Li

Xiaoyan Shen

Wei Gu

Yifei Shen

Wenmao Wu

Xintao Zhao

Hong Lan

Bang Fu

Xiaojing Tang

Bo Zhan

Dongjie Feng

Yongxin Ke

Zhongyan Chen

Rongwen Yang

Yuan Lu

Jiangqi He

Boyan Li

Shuibiao Fu

Xiao Zhou

Haima Al

Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Immunomodulators, compositions and methods thereof

The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.

Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

Compound functioning as bromodomain protein inhibitor, and composition

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds. 

Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis. 

ERK inhibitor and use thereof

An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. 

FGFR inhibitor and application thereof

The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein. 

Benzimidazole derivatives, preparation methods and uses thereof

Disclosed is Icotinib phosphate (i.e., the compound of Formula (I)) and polymorph forms thereof, and methods of preparing and using them. 

Polymorphic forms of icotinib phosphate and uses thereof

The present invention relates to the polymorphic forms of the compound of Formula I, preparation thereof and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition. 

Polymorphic forms of icotinib and uses thereof

Provided are Icotinib maleate (the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them. 

Polymorphic forms of icotinib maleate and uses thereof

The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.

Glucagon like peptide analogs, composition, and method of use

The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof

Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar. 

Glucagon-like peptide-1 analogues and uses thereof

Growing community of inventors

Beijing, China

Lieming Ding